hERGスクリーニングの世界市場

hERGスクリーニングの世界市場は2030年までに49億米ドルに到達

2024年に24億米ドルと推定されるhERGスクリーニングの世界市場は、2024年から2030年にかけてCAGR 12.7%で成長し、2030年には49億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである遺伝子KCNH2は、CAGR 14.0%を記録し、分析期間終了までに37億米ドルに達すると予測されます。変異型KCNH2セグメントの成長率は、分析期間中CAGR 9.5％と推定されます。

米国市場は6億5,480万米ドルと推定、中国はCAGR17.3％で成長すると予測

米国のhERGスクリーニング市場は、2024年に6億5,480万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは17.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.1％と11.4％と予測されています。欧州では、ドイツがCAGR 10.1%で成長すると予測されています。

世界のhERGスクリーニング市場- 主要動向と促進要因のまとめ

現代の医薬品開発パイプラインにおいてhERGスクリーニングが重要なのはなぜか？

hERG（human Ether-a-go-go-Related Gene）スクリーニングは、KCNH2遺伝子によってコードされる心筋カリウムイオンチャネルを阻害する化合物の可能性を評価するために使用される、創薬における重要な安全性アッセイです。このチャネルが阻害されると、QT間隔が延長し、Torsades de Pointesのような生命を脅かす不整脈のリスクが高まる可能性があります。そのため、hERGスクリーニングは、FDA、EMA、ICHを含む世界の規制当局により、前臨床安全性薬理学の必須要素となっています。

hERGスクリーニングは心臓の安全性に影響するため、心臓血管薬だけでなく、腫瘍、中枢神経系、感染症などの治療薬にも不可欠です。潜在的な心毒性を示す薬剤候補は、通常、パイプラインの初期段階で変更、優先順位付けの中止、または中止され、企業は下流工程で何百万ドルものコストを節約することができます。このスクリーニングはリード化合物の最適化にも不可欠であり、医薬品化学者は動物試験やヒト試験に入る前に化合物のリスクを減らし、改良することができます。

hERGアッセイの精度とスループットを向上させる技術は？

ハイスループットスクリーニング（HTS）、パッチクランプ電気生理学、予測計算モデリングにおける最近の進歩は、hERG試験の精度とスケーラビリティを著しく向上させています。QPatchやSyncroPatchのような自動化された平面パッチクランププラットフォームは、労力と時間の投資を抑えながら、イオンチャネル活性のハイコンテントスクリーニングを可能にします。同様に、蛍光ベースのアッセイや電圧感受性色素は、初期段階の化合物プロファイリングに費用対効果の高い選択肢を提供します。

インシリコ・モデリングと機械学習は現在、化学構造に基づいてhERG活性を予測するために応用されており、徹底的なin vitro試験の必要性を減らしています。hERG評価のための生理学的に適切なプラットフォームとして、ヒトiPSC由来の心筋細胞の使用も、特にComprehensive In Vitro Proarrhythmia Assay（CiPA）イニシアチブのもとで普及しつつあります。これらの技術は、前臨床心毒性評価における予測可能性と規制との整合性を改善しつつあります。

hERGスクリーニングの需要をリードするセクターと地域は？

製薬会社やバイオテクノロジー企業がhERGスクリーニングの主要なエンドユーザーであり、前臨床開発の初期段階や規制当局への申請段階でこれらのアッセイを統合しています。CRO（医薬品開発業務受託機関）もhERGスクリーニングサービスの主要なプロバイダーであり、医薬品開発企業にスケーラブルなアッセイのアウトソーシング機能を提供しています。学術機関や毒物学研究所は、心臓の安全性評価やチャネルパチー研究にhERGモデルを利用しています。

地域的には、北米がhERGスクリーニング市場を独占しており、これは集中的な医薬品開発活動、厳格な規制要件、先進的な研究所インフラに牽引されています。次いで欧州が、レギュラトリーサイエンスと官民の医薬品開発協力に強い関心を寄せています。アジア太平洋は高成長地域として浮上しており、特に中国とインドでは医薬品研究開発費が増加し、世界の医薬品メーカーが初期の毒性試験をアウトソーシングしています。

hERGスクリーニング市場の成長はいくつかの要因によってもたらされる...

hERGスクリーニング市場の成長は、安全性薬理学の義務付け、医薬品開発の複雑さ、技術主導のスクリーニング革新に関連するいくつかの要因によって牽引されています。自動パッチクランプシステム、ヒト関連細胞モデル、予測AIベースのスクリーニングツールの進歩により、スループット、精度、規制遵守が大幅に向上しています。これらの技術革新は、臨床的失敗のリスクを最小限に抑えながら、医薬品安全性プロファイリングの決定までの時間を短縮しています。

最終用途側では、特に腫瘍学と中枢神経系薬剤を中心とする世界の医薬品パイプラインの拡大により、hERG責任試験を必要とする化合物の量が増加しています。個別化医療や標的治療の台頭により、正確な心毒性スクリーニングがさらに必要とされています。ICH S7BやCiPAイニシアチブのような規制の枠組みは、心臓安全性の主要なバイオマーカーとしてhERGを強調し続け、前臨床ワークフローに不可欠であることを保証しています。安全性基準や開発スケジュールがますます厳しくなる中、新薬開発のリスク回避と迅速化において、hERGスクリーニングは不可欠なものとなりつつあります。

セグメント

タイプ（遺伝子KCNH2タイプ、変異型KCNH2タイプ）、イオンチャネル（電圧ゲート型イオンチャネル、リガンドゲート型イオンチャネル）、アプリケーション（抗不整脈アプリケーション、抗精神病アプリケーション、抗生物質アプリケーション、その他のアプリケーション）

調査対象企業の例（注目の33社）

• ApconiX Ltd.
• Aurigene Pharmaceutical Services
• Charles River Laboratories
• Creative Bioarray
• Cyprotex（Evotec）
• Eurofins Discovery
• Evotec SE
• Mediford
• Metrion Biosciences
• Molecular Devices
• Reaction Biology Corporation
• Thermo Fisher Scientific
• WuXi AppTec
• Eurofins Discovery
• Charles River Laboratories
• ApconiX Ltd.
• Creative Bioarray
• Cyprotex（Evotec）
• Mediford
• Metrion Biosciences

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global hERG Screening Market to Reach US$4.9 Billion by 2030

The global market for hERG Screening estimated at US$2.4 Billion in the year 2024, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2024-2030. Gene KCNH2, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Mutant KCNH2 segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$654.8 Million While China is Forecast to Grow at 17.3% CAGR

The hERG Screening market in the U.S. is estimated at US$654.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global hERG Screening Market - Key Trends & Drivers Summarized

Why Is hERG Screening Critical in Modern Drug Development Pipelines?

hERG (human Ether-a-go-go-Related Gene) screening is a crucial safety assay in drug discovery, used to evaluate a compound’s potential to block the cardiac potassium ion channel encoded by the KCNH2 gene. Inhibition of this channel can lead to QT interval prolongation and increase the risk of life-threatening cardiac arrhythmias such as Torsades de Pointes. As such, hERG screening has become a mandated component of preclinical safety pharmacology by global regulatory agencies including the FDA, EMA, and ICH.

Due to its implications for cardiac safety, hERG screening is essential not only for cardiovascular drugs but also for therapeutics across oncology, CNS, and infectious diseases. Drug candidates that show potential cardiotoxicity are typically modified, deprioritized, or withdrawn early in the pipeline, saving companies millions in downstream costs. This screening is also vital in lead optimization, enabling medicinal chemists to de-risk and refine compounds before entering animal or human studies.

How Are Technologies Advancing the Accuracy and Throughput of hERG Assays?

Recent advances in high-throughput screening (HTS), patch-clamp electrophysiology, and predictive computational modeling have significantly enhanced the precision and scalability of hERG testing. Automated planar patch-clamp platforms such as QPatch and SyncroPatch allow for high-content screening of ion channel activity with reduced labor and time investment. Similarly, fluorescence-based assays and voltage-sensitive dyes provide cost-effective alternatives for early-stage compound profiling.

In silico modeling and machine learning are now being applied to predict hERG liability based on chemical structure, reducing the need for exhaustive in vitro testing. The use of human iPSC-derived cardiomyocytes as a physiologically relevant platform for hERG evaluation is also gaining traction, especially under the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative. These technologies are improving predictability and regulatory alignment in preclinical cardiotoxicity assessment.

Which Sectors and Regions Are Leading hERG Screening Demand?

Pharmaceutical and biotechnology companies represent the primary end-users of hERG screening, integrating these assays during early preclinical development and regulatory submission phases. CROs (Contract Research Organizations) are also major providers of hERG screening services, offering scalable, outsourced assay capabilities to drug developers. Academic institutions and toxicology research labs utilize hERG models for cardiac safety evaluation and channelopathy research.

Geographically, North America dominates the hERG screening market, driven by intensive drug development activity, stringent regulatory requirements, and advanced laboratory infrastructure. Europe follows, with a strong focus on regulatory science and public-private drug development collaborations. Asia-Pacific is emerging as a high-growth region, especially China and India, where pharmaceutical R&D spending is rising and global drugmakers are outsourcing early toxicology studies.

The Growth in the hERG Screening Market Is Driven by Several Factors…

The growth in the hERG screening market is driven by several factors related to safety pharmacology mandates, drug development complexity, and technology-driven screening innovation. Advances in automated patch-clamp systems, human-relevant cell models, and predictive AI-based screening tools have significantly enhanced throughput, accuracy, and regulatory compliance. These innovations are reducing time-to-decision for drug safety profiling while minimizing clinical failure risks.

On the end-use side, the expanding global pharmaceutical pipeline, especially in oncology and CNS drugs, is increasing the volume of compounds requiring hERG liability testing. The rise of personalized medicine and targeted therapies further necessitates precise cardiotoxicity screening. Regulatory frameworks like ICH S7B and the CiPA initiative continue to emphasize hERG as a primary biomarker of cardiac safety, ensuring that it remains integral to preclinical workflows. As safety standards and development timelines grow increasingly stringent, hERG screening is becoming indispensable in de-risking and accelerating new drug development.

SCOPE OF STUDY:

The report analyzes the hERG Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Gene KCNH2 Type, Mutant KCNH2 Type); Ion Channel (Voltage-Gated Ion Channel, Ligand-Gated Ion Channel); Application (Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• ApconiX Ltd.
• Aurigene Pharmaceutical Services
• Charles River Laboratories
• Creative Bioarray
• Cyprotex (Evotec)
• Eurofins Discovery
• Evotec SE
• Mediford
• Metrion Biosciences
• Molecular Devices
• Reaction Biology Corporation
• Thermo Fisher Scientific
• WuXi AppTec
• Eurofins Discovery
• Charles River Laboratories
• ApconiX Ltd.
• Creative Bioarray
• Cyprotex (Evotec)
• Mediford
• Metrion Biosciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • hERG Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Regulatory Scrutiny of Cardiac Safety Profiles Drives Demand for Robust hERG Screening Assays
  • FDA and ICH Guidelines Mandating QT Prolongation Risk Assessment Propel hERG Screening Integration
  • Early Toxicology Prioritization in Drug Discovery Enhances Market Demand for High-Throughput hERG Assays
  • Growth of Predictive Cardiotoxicity Platforms Fuels Innovation in Automated and AI-Powered hERG Screening
  • Expansion of Preclinical Outsourcing and CRO Services Boosts Global Accessibility of hERG Testing Capabilities
  • Advancements in In Vitro Ion Channel Electrophysiology Technologies Strengthen Assay Precision
  • Surging Small Molecule and Biologics Pipelines Accelerate Use of hERG Screening in Risk Evaluation
  • Demand for Integrated ADMET Profiling Solutions Spurs Bundling of hERG Screening With Other Safety Assays
  • hERG Patch Clamp and Automated Electrophysiology Systems Drive Adoption in Pharma R&D Labs
  • Increased Focus on Data-Driven Drug Design Strengthens Use of hERG Assays in Early Compound Screening
  • Rising Concern Over Drug Withdrawals and Black Box Warnings Underscores Importance of Proactive hERG Testing
  • Expansion of Stem Cell-Derived Cardiomyocyte Models Improves Physiological Relevance in hERG Assays
  • Development of Label-Free Technologies and Optical Assays Enhances Scalability of hERG Screening
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World hERG Screening Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for hERG Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for hERG Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for hERG Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Gene KCNH2 Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Gene KCNH2 Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Gene KCNH2 Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Mutant KCNH2 Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Mutant KCNH2 Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Mutant KCNH2 Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Voltage-Gated Ion Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Voltage-Gated Ion Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Voltage-Gated Ion Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Ligand-Gated Ion Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Ligand-Gated Ion Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Ligand-Gated Ion Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antiarrhythmic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antiarrhythmic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Antiarrhythmic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Antipsychotic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Antipsychotic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Antipsychotic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Antibiotics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Antibiotics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Antibiotics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for hERG Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for hERG Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for hERG Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for hERG Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for hERG Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for hERG Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for hERG Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for hERG Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for hERG Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for hERG Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for hERG Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • hERG Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for hERG Screening by Type - Gene KCNH2 Type and Mutant KCNH2 Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for hERG Screening by Type - Percentage Breakdown of Value Sales for Gene KCNH2 Type and Mutant KCNH2 Type for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for hERG Screening by Ion Channel - Voltage-Gated Ion Channel and Ligand-Gated Ion Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for hERG Screening by Ion Channel - Percentage Breakdown of Value Sales for Voltage-Gated Ion Channel and Ligand-Gated Ion Channel for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for hERG Screening by Application - Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for hERG Screening by Application - Percentage Breakdown of Value Sales for Antiarrhythmic Application, Antipsychotic Application, Antibiotics Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION